Who are Adreview's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Posluma, Neuraceq, Flyrcado, FLURPIRIDAZ F 18, Posluma, Ioflupane I 123.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iobenguane-123i.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adreview — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adreview (iobenguane (123I)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioactive Diagnostic Agent. Area: Oncology.

marketed Radioactive Diagnostic Agent Oncology Live · refreshed every 30 min

Target snapshot

Adreview (iobenguane (123I)) — GE HealthCare. Adreview works by binding to specific cells or tissues in the body, allowing for imaging and diagnosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adreview TARGET	iobenguane (123I)	GE HealthCare	marketed	Radioactive Diagnostic Agent		2008-01-01
Posluma	FLOTUFOLASTAT	Blue Earth	marketed	Radioactive Diagnostic Agent [EPC]		2025-01-01
Neuraceq	FLORBETABEN	Life Molecular	marketed	Radioactive Diagnostic Agent [EPC]		2025-01-01
Flyrcado	FLURPIRIDAZ	Ge Hlthcare	marketed	Radioactive Diagnostic Agent [EPC]		2024-01-01
FLURPIRIDAZ F 18	FLURPIRIDAZ F 18		marketed	Radioactive Diagnostic Agent [EPC]		2024-01-01
Posluma	FLOTUFOLASTAT F-18 GALLIUM	Blue Earth	marketed	Radioactive Diagnostic Agent [EPC]	Glutamate carboxypeptidase 2	2023-01-01
Ioflupane I 123	IOFLUPANE	Ge Hlthcare Inc	marketed	Radioactive Diagnostic Agent [EPC]	Dopamine transporter (DaT)	2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioactive Diagnostic Agent class)

GE HealthCare · 2 drugs in this class
· 1 drug in this class
Bracco · 1 drug in this class
Mallinckrodt · 1 drug in this class
Navidea Biopharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adreview — Competitive Intelligence Brief. https://druglandscape.com/ci/iobenguane-123i. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing